Abstract
BackgroundManagement of drug-drug interactions (DDIs) for ensitrelvir, a novel 3-chymotrypsin-like protease inhibitor of SARS-CoV-2 infection is cruci......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
